AustralieFrV1, PascalFrancis, Corpus, bibRecord, 006300

Role of medical history in brain tumour development. Results from the international adult brain tumour study

Identifieur interne : 006300 ( PascalFrancis/Corpus ); précédent : 006299; suivant : 006301

Role of medical history in brain tumour development. Results from the international adult brain tumour study

Auteurs : B. Schlehofer ; M. Blettner ; S. Preston-Martin ; D. Niehoff ; J. Wahrendorf ; A. Arslan ; A. Ahlbom ; W. N. Choi ; G. G. Giles ; G. R. Howe ; J. Little ; F. Menegoz ; P. Ryan

Source :

International journal of cancer [ 0020-7136 ] ; 1999.

RBID : Pascal:99-0375688

Descripteurs français

Pascal (Inist)
- Gliome malin, Intracrânien, Méningiome malin, Antécédent, Association morbide, Epilepsie, Chimiothérapie, Anticonvulsivant, Asthme, Allergie, Eczéma, Etude multicentrique, Etude cas témoin, Homme.

English descriptors

KwdEn :
- Allergy, Antecedent, Anticonvulsant, Asthma, Case control study, Chemotherapy, Concomitant disease, Eczema, Epilepsy, Human, Intracranial, Malignant glioma, Malignant meningioma, Multicenter study.

Abstract

In an international population-based case-control study carried out in 8 centres in 6 countries, we investigated the role of specific medical conditions in the aetiology of brain tumours in adults. Recruited were 1,178 glioma and 331 meningioma cases and 2,493 age- and gender-matched population controls. Only medical conditions occurring at least 2 years before brain tumour diagnosis were considered. Relative risks (RRs) and 95% confidence intervals (Cls) were estimated using a conditional logistic regression model. Heterogeneity between centres was tested. No association between meningioma and previous medical conditions was observed. For glioma, there was an increased risk associated with epilepsy (RR = 6.55, 95% Cl 3,40-12.63), but this was considerably weaker for epilepsy of more than 20 years duration. The risk remained elevated after adjustment for use of anti-epileptic drugs. There was a statistically significant inverse association between glioma and all allergic diseases combined (RR = 0.59, 95% Cl 0.49-0.71); this was also observed for specific allergic conditions, namely, asthma and eczema. Subjects who reported a history of infectious diseases (e.g., colds, flu) showed a 30% reduction in risk (RR = 0.72, 95% Cl 0.61-0.85). The decreased risks for glioma in subjects reporting a history of allergic conditions or infectious diseases may indicate an influence of immunological factors on the development of glioma. The association between glioma and epilepsy has to be interpreted cautiously and needs further investigation.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0020-7136`
A02	`01`			`@0 IJCNAW`
A03		`1`		`@0 Int. j. cancer`
A05				`@2 82`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Role of medical history in brain tumour development. Results from the international adult brain tumour study`
A11	`01`	`1`		`@1 SCHLEHOFER (B.)`
A11	`02`	`1`		`@1 BLETTNER (M.)`
A11	`03`	`1`		`@1 PRESTON-MARTIN (S.)`
A11	`04`	`1`		`@1 NIEHOFF (D.)`
A11	`05`	`1`		`@1 WAHRENDORF (J.)`
A11	`06`	`1`		`@1 ARSLAN (A.)`
A11	`07`	`1`		`@1 AHLBOM (A.)`
A11	`08`	`1`		`@1 CHOI (W. N.)`
A11	`09`	`1`		`@1 GILES (G. G.)`
A11	`10`	`1`		`@1 HOWE (G. R.)`
A11	`11`	`1`		`@1 LITTLE (J.)`
A11	`12`	`1`		`@1 MENEGOZ (F.)`
A11	`13`	`1`		`@1 RYAN (P.)`
A14	`01`			`@1 German Cancer Research Centre, Division of Epidemiology @2 Heidelberg @3 DEU @Z 1 aut. @Z 4 aut. @Z 5 aut.`
A14	`02`			`@1 Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld @2 Bielefeld @3 DEU @Z 2 aut. @Z 6 aut.`
A14	`03`			`@1 University of Southern California School of Medicine @2 Los Angeles, CA @3 USA @Z 3 aut.`
A14	`04`			`@1 Division of Epidemiology, Institute for Environmental Medicine @2 Stockholm @3 SWE @Z 7 aut.`
A14	`05`			`@1 Anti Cancer Council of Victoria @2 Victoria @3 AUS @Z 9 aut.`
A14	`06`			`@1 Division of Epidemiology, Columbia University School of Public Health @2 New York, NY @3 USA @Z 10 aut.`
A14	`07`			`@1 Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill @2 Aberdeen @3 GBR @Z 11 aut.`
A14	`08`			`@1 Registre du Cancer du Department de l'Isère @2 Meylan @3 FRA @Z 12 aut.`
A14	`09`			`@1 Department of Public Health, University of Adelaide @2 Adelaide @3 AUS @Z 13 aut.`
A20				`@1 155-160`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13027 @5 354000085485140010`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 33 ref.`
A47	`01`	`1`		`@0 99-0375688`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 International journal of cancer`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 In an international population-based case-control study carried out in 8 centres in 6 countries, we investigated the role of specific medical conditions in the aetiology of brain tumours in adults. Recruited were 1,178 glioma and 331 meningioma cases and 2,493 age- and gender-matched population controls. Only medical conditions occurring at least 2 years before brain tumour diagnosis were considered. Relative risks (RRs) and 95% confidence intervals (Cls) were estimated using a conditional logistic regression model. Heterogeneity between centres was tested. No association between meningioma and previous medical conditions was observed. For glioma, there was an increased risk associated with epilepsy (RR = 6.55, 95% Cl 3,40-12.63), but this was considerably weaker for epilepsy of more than 20 years duration. The risk remained elevated after adjustment for use of anti-epileptic drugs. There was a statistically significant inverse association between glioma and all allergic diseases combined (RR = 0.59, 95% Cl 0.49-0.71); this was also observed for specific allergic conditions, namely, asthma and eczema. Subjects who reported a history of infectious diseases (e.g., colds, flu) showed a 30% reduction in risk (RR = 0.72, 95% Cl 0.61-0.85). The decreased risks for glioma in subjects reporting a history of allergic conditions or infectious diseases may indicate an influence of immunological factors on the development of glioma. The association between glioma and epilepsy has to be interpreted cautiously and needs further investigation.
C02	`01`	`X`		`@0 002B17E`
C03	`01`	`X`	`FRE`	`@0 Gliome malin @5 01`
C03	`01`	`X`	`ENG`	`@0 Malignant glioma @5 01`
C03	`01`	`X`	`SPA`	`@0 Glioma maligno @5 01`
C03	`02`	`X`	`FRE`	`@0 Intracrânien @5 02`
C03	`02`	`X`	`ENG`	`@0 Intracranial @5 02`
C03	`02`	`X`	`SPA`	`@0 Intracraneal @5 02`
C03	`03`	`X`	`FRE`	`@0 Méningiome malin @5 03`
C03	`03`	`X`	`ENG`	`@0 Malignant meningioma @5 03`
C03	`03`	`X`	`SPA`	`@0 Meningioma maligno @5 03`
C03	`04`	`X`	`FRE`	`@0 Antécédent @5 04`
C03	`04`	`X`	`ENG`	`@0 Antecedent @5 04`
C03	`04`	`X`	`SPA`	`@0 Antecedente @5 04`
C03	`05`	`X`	`FRE`	`@0 Association morbide @5 06`
C03	`05`	`X`	`ENG`	`@0 Concomitant disease @5 06`
C03	`05`	`X`	`SPA`	`@0 Asociación morbosa @5 06`
C03	`06`	`X`	`FRE`	`@0 Epilepsie @5 07`
C03	`06`	`X`	`ENG`	`@0 Epilepsy @5 07`
C03	`06`	`X`	`SPA`	`@0 Epilepsia @5 07`
C03	`07`	`X`	`FRE`	`@0 Chimiothérapie @5 08`
C03	`07`	`X`	`ENG`	`@0 Chemotherapy @5 08`
C03	`07`	`X`	`SPA`	`@0 Quimioterapia @5 08`
C03	`08`	`X`	`FRE`	`@0 Anticonvulsivant @5 09`
C03	`08`	`X`	`ENG`	`@0 Anticonvulsant @5 09`
C03	`08`	`X`	`SPA`	`@0 Anticonvulsivante @5 09`
C03	`09`	`X`	`FRE`	`@0 Asthme @5 10`
C03	`09`	`X`	`ENG`	`@0 Asthma @5 10`
C03	`09`	`X`	`SPA`	`@0 Asma @5 10`
C03	`10`	`X`	`FRE`	`@0 Allergie @5 11`
C03	`10`	`X`	`ENG`	`@0 Allergy @5 11`
C03	`10`	`X`	`SPA`	`@0 Alergia @5 11`
C03	`11`	`X`	`FRE`	`@0 Eczéma @5 13`
C03	`11`	`X`	`ENG`	`@0 Eczema @5 13`
C03	`11`	`X`	`SPA`	`@0 Eczema @5 13`
C03	`12`	`X`	`FRE`	`@0 Etude multicentrique @5 17`
C03	`12`	`X`	`ENG`	`@0 Multicenter study @5 17`
C03	`12`	`X`	`SPA`	`@0 Estudio multicéntrico @5 17`
C03	`13`	`X`	`FRE`	`@0 Etude cas témoin @5 18`
C03	`13`	`X`	`ENG`	`@0 Case control study @5 18`
C03	`13`	`X`	`SPA`	`@0 Estudio caso control @5 18`
C03	`14`	`X`	`FRE`	`@0 Homme @5 19`
C03	`14`	`X`	`ENG`	`@0 Human @5 19`
C03	`14`	`X`	`SPA`	`@0 Hombre @5 19`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Tumeur maligne @5 40`
C07	`04`	`X`	`ENG`	`@0 Malignant tumor @5 40`
C07	`04`	`X`	`SPA`	`@0 Tumor maligno @5 40`
C07	`05`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 61`
C07	`05`	`X`	`ENG`	`@0 Respiratory disease @5 61`
C07	`05`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 61`
C07	`06`	`X`	`FRE`	`@0 Bronchopneumopathie obstructive @5 62`
C07	`06`	`X`	`ENG`	`@0 Obstructive pulmonary disease @5 62`
C07	`06`	`X`	`SPA`	`@0 Broncopneumopatía obstructiva @5 62`
C07	`07`	`X`	`FRE`	`@0 Immunopathologie @5 63`
C07	`07`	`X`	`ENG`	`@0 Immunopathology @5 63`
C07	`07`	`X`	`SPA`	`@0 Inmunopatología @5 63`
C07	`08`	`X`	`FRE`	`@0 Peau pathologie @5 71`
C07	`08`	`X`	`ENG`	`@0 Skin disease @5 71`
C07	`08`	`X`	`SPA`	`@0 Piel patología @5 71`
N21				`@1 242`

Format Inist (serveur)

NO :	PASCAL 99-0375688 INIST
ET :	Role of medical history in brain tumour development. Results from the international adult brain tumour study
AU :	SCHLEHOFER (B.); BLETTNER (M.); PRESTON-MARTIN (S.); NIEHOFF (D.); WAHRENDORF (J.); ARSLAN (A.); AHLBOM (A.); CHOI (W. N.); GILES (G. G.); HOWE (G. R.); LITTLE (J.); MENEGOZ (F.); RYAN (P.)
AF :	German Cancer Research Centre, Division of Epidemiology/Heidelberg/Allemagne (1 aut., 4 aut., 5 aut.); Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld/Bielefeld/Allemagne (2 aut., 6 aut.); University of Southern California School of Medicine/Los Angeles, CA/Etats-Unis (3 aut.); Division of Epidemiology, Institute for Environmental Medicine/Stockholm/Suède (7 aut.); Anti Cancer Council of Victoria/Victoria/Australie (9 aut.); Division of Epidemiology, Columbia University School of Public Health/New York, NY/Etats-Unis (10 aut.); Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill/Aberdeen/Royaume-Uni (11 aut.); Registre du Cancer du Department de l'Isère/Meylan/France (12 aut.); Department of Public Health, University of Adelaide/Adelaide/Australie (13 aut.)
DT :	Publication en série; Niveau analytique
SO :	International journal of cancer; ISSN 0020-7136; Coden IJCNAW; Etats-Unis; Da. 1999; Vol. 82; No. 2; Pp. 155-160; Bibl. 33 ref.
LA :	Anglais
EA :	In an international population-based case-control study carried out in 8 centres in 6 countries, we investigated the role of specific medical conditions in the aetiology of brain tumours in adults. Recruited were 1,178 glioma and 331 meningioma cases and 2,493 age- and gender-matched population controls. Only medical conditions occurring at least 2 years before brain tumour diagnosis were considered. Relative risks (RRs) and 95% confidence intervals (Cls) were estimated using a conditional logistic regression model. Heterogeneity between centres was tested. No association between meningioma and previous medical conditions was observed. For glioma, there was an increased risk associated with epilepsy (RR = 6.55, 95% Cl 3,40-12.63), but this was considerably weaker for epilepsy of more than 20 years duration. The risk remained elevated after adjustment for use of anti-epileptic drugs. There was a statistically significant inverse association between glioma and all allergic diseases combined (RR = 0.59, 95% Cl 0.49-0.71); this was also observed for specific allergic conditions, namely, asthma and eczema. Subjects who reported a history of infectious diseases (e.g., colds, flu) showed a 30% reduction in risk (RR = 0.72, 95% Cl 0.61-0.85). The decreased risks for glioma in subjects reporting a history of allergic conditions or infectious diseases may indicate an influence of immunological factors on the development of glioma. The association between glioma and epilepsy has to be interpreted cautiously and needs further investigation.
CC :	002B17E
FD :	Gliome malin; Intracrânien; Méningiome malin; Antécédent; Association morbide; Epilepsie; Chimiothérapie; Anticonvulsivant; Asthme; Allergie; Eczéma; Etude multicentrique; Etude cas témoin; Homme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Tumeur maligne; Appareil respiratoire pathologie; Bronchopneumopathie obstructive; Immunopathologie; Peau pathologie
ED :	Malignant glioma; Intracranial; Malignant meningioma; Antecedent; Concomitant disease; Epilepsy; Chemotherapy; Anticonvulsant; Asthma; Allergy; Eczema; Multicenter study; Case control study; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Malignant tumor; Respiratory disease; Obstructive pulmonary disease; Immunopathology; Skin disease
SD :	Glioma maligno; Intracraneal; Meningioma maligno; Antecedente; Asociación morbosa; Epilepsia; Quimioterapia; Anticonvulsivante; Asma; Alergia; Eczema; Estudio multicéntrico; Estudio caso control; Hombre
LO :	INIST-13027.354000085485140010
ID :	99-0375688

Links to Exploration step

Pascal:99-0375688

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Role of medical history in brain tumour development. Results from the international adult brain tumour study</title>
<author><name sortKey="Schlehofer, B" sort="Schlehofer, B" uniqKey="Schlehofer B" first="B." last="Schlehofer">B. Schlehofer</name>
<affiliation><inist:fA14 i1="01"><s1>German Cancer Research Centre, Division of Epidemiology</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Blettner, M" sort="Blettner, M" uniqKey="Blettner M" first="M." last="Blettner">M. Blettner</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld</s1>
<s2>Bielefeld</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Preston Martin, S" sort="Preston Martin, S" uniqKey="Preston Martin S" first="S." last="Preston-Martin">S. Preston-Martin</name>
<affiliation><inist:fA14 i1="03"><s1>University of Southern California School of Medicine</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Niehoff, D" sort="Niehoff, D" uniqKey="Niehoff D" first="D." last="Niehoff">D. Niehoff</name>
<affiliation><inist:fA14 i1="01"><s1>German Cancer Research Centre, Division of Epidemiology</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wahrendorf, J" sort="Wahrendorf, J" uniqKey="Wahrendorf J" first="J." last="Wahrendorf">J. Wahrendorf</name>
<affiliation><inist:fA14 i1="01"><s1>German Cancer Research Centre, Division of Epidemiology</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arslan, A" sort="Arslan, A" uniqKey="Arslan A" first="A." last="Arslan">A. Arslan</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld</s1>
<s2>Bielefeld</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ahlbom, A" sort="Ahlbom, A" uniqKey="Ahlbom A" first="A." last="Ahlbom">A. Ahlbom</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Epidemiology, Institute for Environmental Medicine</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Choi, W N" sort="Choi, W N" uniqKey="Choi W" first="W. N." last="Choi">W. N. Choi</name>
</author>
<author><name sortKey="Giles, G G" sort="Giles, G G" uniqKey="Giles G" first="G. G." last="Giles">G. G. Giles</name>
<affiliation><inist:fA14 i1="05"><s1>Anti Cancer Council of Victoria</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Howe, G R" sort="Howe, G R" uniqKey="Howe G" first="G. R." last="Howe">G. R. Howe</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Epidemiology, Columbia University School of Public Health</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Little, J" sort="Little, J" uniqKey="Little J" first="J." last="Little">J. Little</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill</s1>
<s2>Aberdeen</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menegoz, F" sort="Menegoz, F" uniqKey="Menegoz F" first="F." last="Menegoz">F. Menegoz</name>
<affiliation><inist:fA14 i1="08"><s1>Registre du Cancer du Department de l'Isère</s1>
<s2>Meylan</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ryan, P" sort="Ryan, P" uniqKey="Ryan P" first="P." last="Ryan">P. Ryan</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Public Health, University of Adelaide</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0375688</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0375688 INIST</idno>
<idno type="RBID">Pascal:99-0375688</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">006300</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Role of medical history in brain tumour development. Results from the international adult brain tumour study</title>
<author><name sortKey="Schlehofer, B" sort="Schlehofer, B" uniqKey="Schlehofer B" first="B." last="Schlehofer">B. Schlehofer</name>
<affiliation><inist:fA14 i1="01"><s1>German Cancer Research Centre, Division of Epidemiology</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Blettner, M" sort="Blettner, M" uniqKey="Blettner M" first="M." last="Blettner">M. Blettner</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld</s1>
<s2>Bielefeld</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Preston Martin, S" sort="Preston Martin, S" uniqKey="Preston Martin S" first="S." last="Preston-Martin">S. Preston-Martin</name>
<affiliation><inist:fA14 i1="03"><s1>University of Southern California School of Medicine</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Niehoff, D" sort="Niehoff, D" uniqKey="Niehoff D" first="D." last="Niehoff">D. Niehoff</name>
<affiliation><inist:fA14 i1="01"><s1>German Cancer Research Centre, Division of Epidemiology</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wahrendorf, J" sort="Wahrendorf, J" uniqKey="Wahrendorf J" first="J." last="Wahrendorf">J. Wahrendorf</name>
<affiliation><inist:fA14 i1="01"><s1>German Cancer Research Centre, Division of Epidemiology</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arslan, A" sort="Arslan, A" uniqKey="Arslan A" first="A." last="Arslan">A. Arslan</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld</s1>
<s2>Bielefeld</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ahlbom, A" sort="Ahlbom, A" uniqKey="Ahlbom A" first="A." last="Ahlbom">A. Ahlbom</name>
<affiliation><inist:fA14 i1="04"><s1>Division of Epidemiology, Institute for Environmental Medicine</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Choi, W N" sort="Choi, W N" uniqKey="Choi W" first="W. N." last="Choi">W. N. Choi</name>
</author>
<author><name sortKey="Giles, G G" sort="Giles, G G" uniqKey="Giles G" first="G. G." last="Giles">G. G. Giles</name>
<affiliation><inist:fA14 i1="05"><s1>Anti Cancer Council of Victoria</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Howe, G R" sort="Howe, G R" uniqKey="Howe G" first="G. R." last="Howe">G. R. Howe</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Epidemiology, Columbia University School of Public Health</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Little, J" sort="Little, J" uniqKey="Little J" first="J." last="Little">J. Little</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill</s1>
<s2>Aberdeen</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menegoz, F" sort="Menegoz, F" uniqKey="Menegoz F" first="F." last="Menegoz">F. Menegoz</name>
<affiliation><inist:fA14 i1="08"><s1>Registre du Cancer du Department de l'Isère</s1>
<s2>Meylan</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ryan, P" sort="Ryan, P" uniqKey="Ryan P" first="P." last="Ryan">P. Ryan</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Public Health, University of Adelaide</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">International journal of cancer</title>
<title level="j" type="abbreviated">Int. j. cancer</title>
<idno type="ISSN">0020-7136</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International journal of cancer</title>
<title level="j" type="abbreviated">Int. j. cancer</title>
<idno type="ISSN">0020-7136</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Allergy</term>
<term>Antecedent</term>
<term>Anticonvulsant</term>
<term>Asthma</term>
<term>Case control study</term>
<term>Chemotherapy</term>
<term>Concomitant disease</term>
<term>Eczema</term>
<term>Epilepsy</term>
<term>Human</term>
<term>Intracranial</term>
<term>Malignant glioma</term>
<term>Malignant meningioma</term>
<term>Multicenter study</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Gliome malin</term>
<term>Intracrânien</term>
<term>Méningiome malin</term>
<term>Antécédent</term>
<term>Association morbide</term>
<term>Epilepsie</term>
<term>Chimiothérapie</term>
<term>Anticonvulsivant</term>
<term>Asthme</term>
<term>Allergie</term>
<term>Eczéma</term>
<term>Etude multicentrique</term>
<term>Etude cas témoin</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In an international population-based case-control study carried out in 8 centres in 6 countries, we investigated the role of specific medical conditions in the aetiology of brain tumours in adults. Recruited were 1,178 glioma and 331 meningioma cases and 2,493 age- and gender-matched population controls. Only medical conditions occurring at least 2 years before brain tumour diagnosis were considered. Relative risks (RRs) and 95% confidence intervals (Cls) were estimated using a conditional logistic regression model. Heterogeneity between centres was tested. No association between meningioma and previous medical conditions was observed. For glioma, there was an increased risk associated with epilepsy (RR = 6.55, 95% Cl 3,40-12.63), but this was considerably weaker for epilepsy of more than 20 years duration. The risk remained elevated after adjustment for use of anti-epileptic drugs. There was a statistically significant inverse association between glioma and all allergic diseases combined (RR = 0.59, 95% Cl 0.49-0.71); this was also observed for specific allergic conditions, namely, asthma and eczema. Subjects who reported a history of infectious diseases (e.g., colds, flu) showed a 30% reduction in risk (RR = 0.72, 95% Cl 0.61-0.85). The decreased risks for glioma in subjects reporting a history of allergic conditions or infectious diseases may indicate an influence of immunological factors on the development of glioma. The association between glioma and epilepsy has to be interpreted cautiously and needs further investigation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0020-7136</s0>
</fA01>
<fA02 i1="01"><s0>IJCNAW</s0>
</fA02>
<fA03 i2="1"><s0>Int. j. cancer</s0>
</fA03>
<fA05><s2>82</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Role of medical history in brain tumour development. Results from the international adult brain tumour study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHLEHOFER (B.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BLETTNER (M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PRESTON-MARTIN (S.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>NIEHOFF (D.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WAHRENDORF (J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ARSLAN (A.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>AHLBOM (A.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>CHOI (W. N.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>GILES (G. G.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>HOWE (G. R.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>LITTLE (J.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>MENEGOZ (F.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>RYAN (P.)</s1>
</fA11>
<fA14 i1="01"><s1>German Cancer Research Centre, Division of Epidemiology</s1>
<s2>Heidelberg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld</s1>
<s2>Bielefeld</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of Southern California School of Medicine</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Epidemiology, Institute for Environmental Medicine</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Anti Cancer Council of Victoria</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Division of Epidemiology, Columbia University School of Public Health</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill</s1>
<s2>Aberdeen</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Registre du Cancer du Department de l'Isère</s1>
<s2>Meylan</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Public Health, University of Adelaide</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA20><s1>155-160</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13027</s2>
<s5>354000085485140010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0375688</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>International journal of cancer</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In an international population-based case-control study carried out in 8 centres in 6 countries, we investigated the role of specific medical conditions in the aetiology of brain tumours in adults. Recruited were 1,178 glioma and 331 meningioma cases and 2,493 age- and gender-matched population controls. Only medical conditions occurring at least 2 years before brain tumour diagnosis were considered. Relative risks (RRs) and 95% confidence intervals (Cls) were estimated using a conditional logistic regression model. Heterogeneity between centres was tested. No association between meningioma and previous medical conditions was observed. For glioma, there was an increased risk associated with epilepsy (RR = 6.55, 95% Cl 3,40-12.63), but this was considerably weaker for epilepsy of more than 20 years duration. The risk remained elevated after adjustment for use of anti-epileptic drugs. There was a statistically significant inverse association between glioma and all allergic diseases combined (RR = 0.59, 95% Cl 0.49-0.71); this was also observed for specific allergic conditions, namely, asthma and eczema. Subjects who reported a history of infectious diseases (e.g., colds, flu) showed a 30% reduction in risk (RR = 0.72, 95% Cl 0.61-0.85). The decreased risks for glioma in subjects reporting a history of allergic conditions or infectious diseases may indicate an influence of immunological factors on the development of glioma. The association between glioma and epilepsy has to be interpreted cautiously and needs further investigation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17E</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Gliome malin</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Malignant glioma</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Glioma maligno</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Intracrânien</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Intracranial</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Intracraneal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Méningiome malin</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Malignant meningioma</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Meningioma maligno</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antécédent</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antecedent</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antecedente</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Association morbide</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Concomitant disease</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Asociación morbosa</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Epilepsie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Epilepsy</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Epilepsia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Anticonvulsivant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Anticonvulsant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Anticonvulsivante</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Asthme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Asthma</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Asma</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Allergie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Allergy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Alergia</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Eczéma</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Eczema</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Eczema</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Etude cas témoin</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Case control study</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Estudio caso control</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Human</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0>
<s5>19</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>61</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Bronchopneumopathie obstructive</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Obstructive pulmonary disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Broncopneumopatía obstructiva</s0>
<s5>62</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>63</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>63</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>63</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Peau pathologie</s0>
<s5>71</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>71</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>71</s5>
</fC07>
<fN21><s1>242</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0375688 INIST</NO>
<ET>Role of medical history in brain tumour development. Results from the international adult brain tumour study</ET>
<AU>SCHLEHOFER (B.); BLETTNER (M.); PRESTON-MARTIN (S.); NIEHOFF (D.); WAHRENDORF (J.); ARSLAN (A.); AHLBOM (A.); CHOI (W. N.); GILES (G. G.); HOWE (G. R.); LITTLE (J.); MENEGOZ (F.); RYAN (P.)</AU>
<AF>German Cancer Research Centre, Division of Epidemiology/Heidelberg/Allemagne (1 aut., 4 aut., 5 aut.); Department of Epidemiology and Medical Statistics, School of Public Health, University of Bielefeld/Bielefeld/Allemagne (2 aut., 6 aut.); University of Southern California School of Medicine/Los Angeles, CA/Etats-Unis (3 aut.); Division of Epidemiology, Institute for Environmental Medicine/Stockholm/Suède (7 aut.); Anti Cancer Council of Victoria/Victoria/Australie (9 aut.); Division of Epidemiology, Columbia University School of Public Health/New York, NY/Etats-Unis (10 aut.); Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill/Aberdeen/Royaume-Uni (11 aut.); Registre du Cancer du Department de l'Isère/Meylan/France (12 aut.); Department of Public Health, University of Adelaide/Adelaide/Australie (13 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>International journal of cancer; ISSN 0020-7136; Coden IJCNAW; Etats-Unis; Da. 1999; Vol. 82; No. 2; Pp. 155-160; Bibl. 33 ref.</SO>
<LA>Anglais</LA>
<EA>In an international population-based case-control study carried out in 8 centres in 6 countries, we investigated the role of specific medical conditions in the aetiology of brain tumours in adults. Recruited were 1,178 glioma and 331 meningioma cases and 2,493 age- and gender-matched population controls. Only medical conditions occurring at least 2 years before brain tumour diagnosis were considered. Relative risks (RRs) and 95% confidence intervals (Cls) were estimated using a conditional logistic regression model. Heterogeneity between centres was tested. No association between meningioma and previous medical conditions was observed. For glioma, there was an increased risk associated with epilepsy (RR = 6.55, 95% Cl 3,40-12.63), but this was considerably weaker for epilepsy of more than 20 years duration. The risk remained elevated after adjustment for use of anti-epileptic drugs. There was a statistically significant inverse association between glioma and all allergic diseases combined (RR = 0.59, 95% Cl 0.49-0.71); this was also observed for specific allergic conditions, namely, asthma and eczema. Subjects who reported a history of infectious diseases (e.g., colds, flu) showed a 30% reduction in risk (RR = 0.72, 95% Cl 0.61-0.85). The decreased risks for glioma in subjects reporting a history of allergic conditions or infectious diseases may indicate an influence of immunological factors on the development of glioma. The association between glioma and epilepsy has to be interpreted cautiously and needs further investigation.</EA>
<CC>002B17E</CC>
<FD>Gliome malin; Intracrânien; Méningiome malin; Antécédent; Association morbide; Epilepsie; Chimiothérapie; Anticonvulsivant; Asthme; Allergie; Eczéma; Etude multicentrique; Etude cas témoin; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Tumeur maligne; Appareil respiratoire pathologie; Bronchopneumopathie obstructive; Immunopathologie; Peau pathologie</FG>
<ED>Malignant glioma; Intracranial; Malignant meningioma; Antecedent; Concomitant disease; Epilepsy; Chemotherapy; Anticonvulsant; Asthma; Allergy; Eczema; Multicenter study; Case control study; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Malignant tumor; Respiratory disease; Obstructive pulmonary disease; Immunopathology; Skin disease</EG>
<SD>Glioma maligno; Intracraneal; Meningioma maligno; Antecedente; Asociación morbosa; Epilepsia; Quimioterapia; Anticonvulsivante; Asma; Alergia; Eczema; Estudio multicéntrico; Estudio caso control; Hombre</SD>
<LO>INIST-13027.354000085485140010</LO>
<ID>99-0375688</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006300 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 006300 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0375688
   |texte=   Role of medical history in brain tumour development. Results from the international adult brain tumour study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Role of medical history in brain tumour development. Results from the international adult brain tumour study

Role of medical history in brain tumour development. Results from the international adult brain tumour study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri